A study showed AP administration significantly protected against HFD-induced liver injury in rats by attenuating ALT and AST elevation, reduced mild inflammation, micro-vesicular steatosis, and macro-vesicular steatosis in hepatocytes and attenuated hepatic lipid accumulation in NAFLD rats. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.